Conservative surgical and drug therapies for adenomyosis Medicine

Fan Y; Yiyue Fan; Shaomi Zhu; Zhu S; Liang X; Xin Liang

doi:10.1016/j.repbio.2022.100664

Conservative surgical and drug therapies for adenomyosis Medicine

Fan Y, Yiyue Fan, Shaomi Zhu, Zhu S, Liang X, Xin Liang

Reproductive biology · 2022 · vol. 22(3) , pp. 100664 · doi:10.1016/j.repbio.2022.100664 · PMID:35689959 · W4282917679

review OA: closed CC0 ⤵ 9 in-corpus citations

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper reviews conservative surgical and drug therapies for adenomyosis, offering a summary of current treatment options.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Adenomyosis is a benign invasion/infiltration of endometrial glands and stroma in the uterine myometrium. The optimal choice of adenomyosis treatment remains a subject of discussion. For patients with adenomyosis without fertility requirements, hysterectomy can be performed by laparotomy or laparoscopic surgery to eliminate symptoms. However, this is an inadequate option for women who want to preserve fertility or avoid more extensive surgery. To summarize the medicine and conservative surgery treatment for adenomyosis. An extensive literature search was performed using PubMed, Web of Science, Embase, Ovid Medline, Cochrane Central Register of Controlled Trials, Google Scholar and China National Knowledge Infrastructure (CNKI) without language restriction. The search terms were as follows: adenomyomas, adenomyosis, conservative therapy; combined therapy; medicine; surgery. The search included all titles and abstracts assessing conservative treatment for adenomyosis including medical and surgical therapy. All published papers were analyzed if considered relevant. Increasing current conservative treatments will not only improve the quality of life of the patients but also preserve fertility. Therefore, conservative treatment is extremely important for patients with fertility requirements or a strong desire to retain the uterus. Conservative treatment for adenomyosis may become a future trend in the field of gynecology.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (60)

Cited by (9)

Source provenance

europepmc: last seen: 2026-08-05T06:13:34.187606+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-07-02T06:07:48.629004+00:00

License: CC0 · commercial use OK

[1] A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy via openalex

[2] Adenomyosis and Infertility—Review of Medical and Surgical Approaches via openalex

[3] Adenomyosis and in vitro fertilization impacts - A literature review via openalex

[4] Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease via openalex

[5] Association of uterine wall thickness with pregnancy outcome following uterine‐sparing surgery for diffuse uterine adenomyosis via openalex

[6] A systematic review of outcome reporting and outcome measures in studies investigating uterine-sparing treatment for adenomyosis via openalex

[7] Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results via openalex

[8] [Clinical study of high intensity focused ultrasound ablation combined with GnRH-a and LNG-IUS for the treatment of adenomyosis]. via openalex

[9] Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial via openalex

[10] Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial via openalex

[11] Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis via openalex

[12] Danazol for pelvic pain associated with endometriosis via openalex

[13] Diagnosing adenomyosis: an integrated clinical and imaging approach via openalex

[14] Dienogest suppresses cellular proliferation status of endometrial polyps and acts differently depending on the morphological type via openalex

[15] Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging via openalex

[16] Effect of pretreatment with a levonorgestrel-releasing intrauterine system on IVF and vitrified–warmed embryo transfer outcomes in women with adenomyosis via openalex

[17] Effects of LNG-IUS on nerve growth factor and its receptors expression in patients with adenomyosis via openalex

[18] Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis via openalex

[19] Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. via openalex

[20] Endometrial preparation with Dienogest before hysteroscopic surgery: a systematic review via openalex

[21] Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis via openalex

[22] Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options via openalex

[23] Gonadotropin-releasing hormone agonists and laparoscopy in the treatment of adenomyosis with infertility. via openalex

[24] Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis via openalex

[25] Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis? via openalex

[26] High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility via openalex

[27] High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up via openalex

[28] Is High-intensity Focused Ultrasound Effective for the Treatment of Adenomyosis? A Systematic Review and Meta-analysis via openalex

[29] [Local administration of danazol on pelvic endometriosis and uterine adenomyosis]. via openalex

[30] Long‐term dienogest administration in patients with symptomatic adenomyosis via openalex

[31] Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use via openalex

[32] New paradigms in the conservative surgical and interventional management of adenomyosis via openalex

[33] Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device via openalex

[34] Partial suppression of estradiol: a new strategy in endometriosis management? via openalex

[35] Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest via openalex

[36] Sonographic Signs of Adenomyosis Are Prevalent in Women Undergoing Surgery for Endometriosis and May Suggest a Higher Risk of Infertility via openalex

[37] The rate of euploid miscarriage is increased in the setting of adenomyosis via openalex

[38] Transvaginal sonographic features of diffuse adenomyosis in 18–30‐year‐old nulligravid women without endometriosis: association with symptoms via openalex

[39] Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex

[40] Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration via openalex

[41] Uterine Artery Embolisation for Symptomatic Adenomyosis with Polyzene F-Coated Hydrogel Microspheres: Three-Year Clinical Follow-Up Using UFS–QoL Questionnaire via openalex

[42] Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire via openalex

[43] W2739010978 via openalex

[44] W3094320124 via openalex

[45] W2736858912 via openalex

[46] W2046867627 via openalex

[47] W3186998543 via openalex

[48] W2037855713 via openalex

[49] W2034183046 via openalex

[50] W1979037641 via openalex

[51] W3203416324 via openalex

[52] W6688370089 via openalex

[53] W6705979222 via openalex

[54] W6714449989 via openalex

[55] W6727974563 via openalex

[56] W6801755490 via openalex

[57] W2997726328 via openalex

[58] W6824378097 via openalex

[59] W2943838538 via openalex

[60] W2790094279 via openalex